Methods to extend health-span and treat age-related diseases

An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in a method of treating or preventing an age-related disease/condition is selected from:

• frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related cardiovascular disease, age-related hypertension, age-related renal disease and age-related skin disease.

Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing an age-related disease/condition selected from:

• frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related non-alcoholic steatohepatitis (NASH), age-related cardiovascular disease, age-related hypertension, age-related renal disease and age-related skin disease.

An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in a method of treating or preventing frailty.

Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing frailty.

A method of treating or preventing frailty, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject.

An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in a method of treating or preventing an age-related change in body composition.

Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing an age-related change in body composition.

A method of treating or preventing an age-related change in body composition, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject.

An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in a method of increasing the healthspan of a subject.

Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of increasing the healthspan of a subject.

A method of increasing the healthspan of a subject, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to the subject.